Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 2,870,000 shares, a drop of 7.1% from the November 15th total of 3,090,000 shares. Based on an average daily volume of 263,800 shares, the short-interest ratio is currently 10.9 days.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Stifel Nicolaus boosted their price target on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th. Finally, Lifesci Capital started coverage on Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $29.17.

Celcuity Stock Up 0.3 %

NASDAQ CELC traded up $0.04 during trading on Tuesday, reaching $12.59. 33,831 shares of the company’s stock were exchanged, compared to its average volume of 276,164. The company has a 50 day moving average price of $14.29 and a two-hundred day moving average price of $15.47. The stock has a market cap of $467.47 million, a P/E ratio of -4.76 and a beta of 0.74. Celcuity has a 1 year low of $11.51 and a 1 year high of $22.19. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.

Hedge Funds Weigh In On Celcuity

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CELC. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Celcuity by 7.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Celcuity in the second quarter valued at $888,000. Bank of New York Mellon Corp grew its holdings in shares of Celcuity by 42.7% during the second quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company’s stock worth $1,085,000 after purchasing an additional 19,811 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Celcuity by 27.7% during the second quarter. Rhumbline Advisers now owns 32,464 shares of the company’s stock worth $532,000 after purchasing an additional 7,049 shares in the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.